"Lung Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the LUNG.
| Descriptor ID |
D008175
|
| MeSH Number(s) |
C04.588.894.797.520 C08.381.540 C08.785.520
|
| Concept/Terms |
Lung Neoplasms- Lung Neoplasms
- Pulmonary Neoplasms
- Neoplasms, Lung
- Lung Neoplasm
- Neoplasm, Lung
- Neoplasms, Pulmonary
- Neoplasm, Pulmonary
- Pulmonary Neoplasm
Lung Cancer- Lung Cancer
- Cancer, Lung
- Cancers, Lung
- Lung Cancers
- Pulmonary Cancer
- Cancer, Pulmonary
- Cancers, Pulmonary
- Pulmonary Cancers
- Cancer of the Lung
- Cancer of Lung
|
Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Lung Neoplasms".
This graph shows the total number of publications written about "Lung Neoplasms" by people in this website by year, and whether "Lung Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1998 | 7 | 2 | 9 |
| 1999 | 9 | 0 | 9 |
| 2000 | 13 | 2 | 15 |
| 2001 | 4 | 7 | 11 |
| 2002 | 11 | 4 | 15 |
| 2003 | 15 | 6 | 21 |
| 2004 | 16 | 4 | 20 |
| 2005 | 12 | 1 | 13 |
| 2006 | 4 | 2 | 6 |
| 2007 | 19 | 5 | 24 |
| 2008 | 38 | 2 | 40 |
| 2009 | 22 | 8 | 30 |
| 2010 | 25 | 6 | 31 |
| 2011 | 39 | 7 | 46 |
| 2012 | 42 | 6 | 48 |
| 2013 | 33 | 6 | 39 |
| 2014 | 32 | 9 | 41 |
| 2015 | 51 | 8 | 59 |
| 2016 | 49 | 7 | 56 |
| 2017 | 49 | 9 | 58 |
| 2018 | 42 | 10 | 52 |
| 2019 | 49 | 7 | 56 |
| 2020 | 48 | 10 | 58 |
| 2021 | 47 | 2 | 49 |
| 2022 | 50 | 0 | 50 |
| 2023 | 47 | 0 | 47 |
| 2024 | 43 | 5 | 48 |
| 2025 | 51 | 1 | 52 |
| 2026 | 21 | 4 | 25 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non-small cell lung cancer. J Manag Care Spec Pharm. 2026 Aug; 32(8):979-993.
-
Pattern of opioid prescriptions among patients with breast, lung, and colorectal cancer diagnosed with pre-existing chronic non-cancer pain. PLoS One. 2026; 21(7):e0352907.
-
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model. JAMA. 2026 Jul 28; 336(4):323-333.
-
Lymph nodes now optional. Science. 2026 Jul 16; 393(6808):242-243.
-
Methylation signatures distinguish non-small cell lung cancer subtypes and are associated with survival in smokers with lung squamous cell carcinoma. J Natl Cancer Inst. 2026 Jul 01; 118(7):1299-1312.
-
Cellular plasticity as a therapeutic vulnerability: HNF4a is a key target in lung adenocarcinoma. J Clin Invest. 2026 Jul 01; 136(13).
-
A trans-omics gene-smoking interaction study of lung cancer based on consortium data. Am J Respir Crit Care Med. 2026 06 01; 212(6):1115-1128.
-
Aristolochic acid and the risk of female lung cancer: Population-based case-control study in Taiwan. Cancer Epidemiol. 2026 Aug; 103:103131.
-
Genome-wide meta-analysis across East Asian and European populations provides insights into the molecular basis of lung cancer. Genome Med. 2026 05 18; 18(1).